tldrdailynews.com logo

GSK to buy Nuvalent for $10.6B, snagging two experimental lung-cancer drugs

1 min read
Source: Endpoints News
GSK to buy Nuvalent for $10.6B, snagging two experimental lung-cancer drugs
Photo: Endpoints News
TL;DR Summary

GSK plans a $10.6 billion acquisition of Nuvalent to gain two experimental lung-cancer medicines (Zidesamtinib and Neladalkib) currently under FDA review, bolstering its oncology pipeline amid a major biotech deal.

Topics:business#biotech#fda-review#gsk#neladalkib#nuvalent#zidesamtinib
Share this article
  1. GSK to acquire Nuvalent and its two cancer drugs under FDA review for $10.6B  Endpoints News
  2. Nuvalent shares surge 39% after UK's GSK agrees to buy the cancer drugmaker for $10.6 billion  CNBC
  3. GSK to Buy Nuvalent for $10.6 Billion in Oncology Push  WSJ
  4. GSK enters agreement to acquire Nuvalent, Inc.  GSK
  5. GSK to buy US cancer biotech Nuvalent for $10.6bn  Financial Times

Reading Insights

Total Reads

0

Unique Readers

4

Time Saved

3 min

vs 3 min read

Condensed

95%

572 → 30 words

Want the full story? Read the original article

Read on Endpoints News